Uncategorized

AbbVie nears $11B Apogee buy to challenge juggernaut Dupixent

Published

on

If secured, AbbVie will add Apogee’s IL-23 blocker to its current immunology stalwarts Skyrizi and Rinvoq, which have helped the pharma ride out the steep patent cliff left behind from mega-blockbuster drug Humira.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version